[1] FINN R S, IKEDA M, ZHU A X, et al.Phase Ⅰb Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[2] WEN T, JIN C, FACCIORUSSO A, et al.Multidisciplinary Management of Recurrent and Metastatic Hepatocellular Carcinoma after Resection: An International Expert Consensus[J]. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
[3] WU J J, ZHU P, ZHANG Z G, et al.Spontaneous rupture of hepatocellular carcinoma: Optimal timing of partial hepatectomy[J]. Eur J Surg Oncol, 2019, 45(10): 1887-1894.
[4] KUDO M, IKEDA M, MOTOMURA K, et al.A phase 1b study of lenvatinib (LEN) plus nivolumab (NIV) in patients with unresectable hepatocellular carcinoma (uHCC): study 117[J]. J Clin Oncol, 2020, 38(Suppl 4): 513. |
